Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Reversal of opioid overdose,Reversal of opioid-induced respiratory depression,Treatment of opioid-induced pruritus,Diagnosis of opioid dependence
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
60-90 minutes in adults; shorter in neonates (3 hours); prolonged in hepatic impairment (up to 2-3 hours).
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via glucuronidation (UGT2B7) to naloxone-3-glucuronide; minor CYP450 involvement.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: ~70% as metabolites (naloxone-3-glucuronide, naloxone-3-sulfate) and <2% unchanged; biliary/fecal: ~25% primarily as conjugated metabolites.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~50-60% primarily to albumin; less bound than opioids.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
2.0-3.0 L/kg; high due to lipophilicity, distributing rapidly into tissues including brain.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: <2% (extensive first-pass metabolism); Intranasal: ~50%; IM/SC: near 100% with rapid absorption.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required; naloxone is not significantly renally eliminated.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required; naloxone undergoes extensive hepatic metabolism, but no guidelines exist for Child-Pugh adjustments.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
0.01-0.1 mg/kg IV/IM/SC, maximum 2 mg per dose; may repeat every 2-3 minutes as needed.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Use lower initial doses (0.4 mg) and titrate cautiously due to increased sensitivity and risk of withdrawal.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of precipitating severe opioid withdrawal in physically dependent patients; caution in neonates.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
May precipitate acute withdrawal; monitor for recurrent respiratory depression due to short half-life; use caution in opioid-dependent patients and neonates.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to naloxone; acute opioid withdrawal syndrome.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
None. Naloxone is not known to interact with food or beverages.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk; no adequate human studies in pregnant women. Naloxone crosses the placenta but has low bioavailability. Risk in first trimester is unknown; theoretical benefit in opioid reversal outweighs potential risk. Second and third trimesters: no known teratogenicity; may cause withdrawal in opioid-dependent fetus if maternal use reversed.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Naloxone is excreted into breast milk in small amounts. M/P ratio is unknown. Milk levels are low and unlikely to affect nursing infant. Oral bioavailability of naloxone is poor (<2%), so infant exposure via breast milk is minimal. Considered compatible with breastfeeding; use when clinically indicated.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dose adjustment required during pregnancy. Pharmacokinetics of naloxone are not significantly altered by gestational changes. Use standard adult dosing for opioid reversal. Titrate to effect based on clinical response.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Naloxone has a short half-life (30-90 minutes) relative to many opioids, necessitating repeat doses or continuous infusion for long-acting opioid overdoses. In opioid-dependent patients, naloxone can precipitate acute withdrawal, which is distressing but not life-threatening. Use the smallest effective dose to reverse respiratory depression while minimizing withdrawal. Consider intranasal administration for ease of use in community settings; onset is slightly slower than IV but comparable efficacy. Monitor for recurrence of respiratory depression after initial reversal, especially with methadone, buprenorphine, or sustained-release formulations. In neonates, naloxone should be used cautiously due to risk of seizures; it is not recommended for routine resuscitation.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Naloxone is a life-saving emergency medication used to reverse opioid overdose; it has no effect if no opioids are present.,Call 911 immediately after administering naloxone; it is a temporary measure and medical help is essential.,After giving naloxone, stay with the person and monitor their breathing; rescue breaths may be needed.,Naloxone may cause withdrawal symptoms like agitation, nausea, sweating, and rapid heart rate; these are signs it is working.,Store naloxone at room temperature, protect from light, and check expiration dates regularly.,If the person does not respond within 2-3 minutes, a second dose may be given if available.,Even if the person wakes up, do not leave them alone; the effects of some opioids can last longer than naloxone, causing breathing to stop again.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE vs ABSTRAL, answered by our medical review team.
NALOXONE is a Opioid Antagonist that works by Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE is: 0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE is classified as Category A/B. FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk; no adequate human studies in pregnant women. Naloxone crosses the placenta but has low bioavailabil. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.